Gilead Sciences (GILD) On Watch on Idenix News
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Join SI Premium – FREE
Gilead Sciences Inc. (Nasdaq: GILD) could see action today after Idenix Pharmaceuticals' (Nasdaq: IDIX) nucleotide polymerase inhibitor IDX184 for HCV was placed on partial clinical hold due to an adverse clinical cardiac event.
Gilead Sciences has its own nuc for HCV.
GILD is down less than 1 percent, while IDIX is down 39 percent.
Gilead Sciences has its own nuc for HCV.
GILD is down less than 1 percent, while IDIX is down 39 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Buyout firm Vista explores $3B sale of private markets data provider Allvue - Reuters
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
